Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul E Monahan

Showing results (1-10 of 63) with videos related to

Pageof 7
Sort By:
Hematology. American Society of Hematology. Education Program|December 6, 2015
Emerging genetic and pharmacologic therapies for controlling hemostasis: beyond recombinant clotting factorsPaul E Monahan
Thrombosis and Haemostasis|October 9, 2008
Factor IX: Insights from knock-out and genetically engineered micePaul E Monahan
Current Opinion in Hematology|July 16, 2013
Gene therapy for hemophilia: advancing beyond the first clinical successPaul E Monahan, Tong Gui
Thrombosis Research|March 16, 2010
Hemophilic synovitis: factor VII and the potential role of extravascular factor VIIaPaul E Monahan, Junjiang Sun
Current Opinion in Hematology|August 13, 2002
Hemophilia gene therapy: updatePaul E Monahan, Gilbert C White
American Journal of Hematology|November 24, 2004
Factors affecting choice of hemostatic agent for the hemophilia patient with an inhibitor antibodyPaul E Monahan, Louis M Aledort,
Seminars in Thrombosis and Hemostasis|July 16, 2010
Recombinant factor IX for clinical and research usePaul E Monahan, Jorge Di Paola
The New England Journal of Medicine|May 17, 2023
Long-Term Effects of Hemophilia B Gene Therapy. ReplySteven W Pipe, Paul E Monahan
Blood|February 25, 2005
A classification system for cross-reactive material-negative factor XI deficiencyDmitri V Kravtsov, Paul E Monahan, David Gailani
Expert Opinion on Drug Safety|August 9, 2003
Safety of adeno-associated virus gene therapy vectors: a current evaluationPaul E Monahan, Karin Jooss, Mark S Sands
Pageof 7

Showing results (1-10 of 63) with videos related to

Sort By:
Pageof 7
Hematology. American Society of Hematology. Education Program|December 6, 2015
Emerging genetic and pharmacologic therapies for controlling hemostasis: beyond recombinant clotting factorsPaul E Monahan
Thrombosis and Haemostasis|October 9, 2008
Factor IX: Insights from knock-out and genetically engineered micePaul E Monahan
Current Opinion in Hematology|July 16, 2013
Gene therapy for hemophilia: advancing beyond the first clinical successPaul E Monahan, Tong Gui
Thrombosis Research|March 16, 2010
Hemophilic synovitis: factor VII and the potential role of extravascular factor VIIaPaul E Monahan, Junjiang Sun
Current Opinion in Hematology|August 13, 2002
Hemophilia gene therapy: updatePaul E Monahan, Gilbert C White
American Journal of Hematology|November 24, 2004
Factors affecting choice of hemostatic agent for the hemophilia patient with an inhibitor antibodyPaul E Monahan, Louis M Aledort,
Seminars in Thrombosis and Hemostasis|July 16, 2010
Recombinant factor IX for clinical and research usePaul E Monahan, Jorge Di Paola
The New England Journal of Medicine|May 17, 2023
Long-Term Effects of Hemophilia B Gene Therapy. ReplySteven W Pipe, Paul E Monahan
Blood|February 25, 2005
A classification system for cross-reactive material-negative factor XI deficiencyDmitri V Kravtsov, Paul E Monahan, David Gailani
Expert Opinion on Drug Safety|August 9, 2003
Safety of adeno-associated virus gene therapy vectors: a current evaluationPaul E Monahan, Karin Jooss, Mark S Sands
Pageof 7